DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with... Read more.
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with... Read more.
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
AstraZeneca and Daiichi Sankyo’s DATROWAY is the only TROP2-directed antibody drug conjugate to prolong overall survival in this setting vs. chemotherapy, with... Read more.
PharmaEssentia to Present New Clinical Data Supporting the Use of Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026
Two-year and post-hoc SURPASS-ET analyses highlight the impact of treatment timing, with durable responses and improved progression-free survival supporting consideration... Read more.
ISG to Study UKG Pro Ecosystem Service Providers
Upcoming ISG Provider Lens® report will evaluate providers that modernize workforce operations with AI, data integration and continuous optimization STAMFORD, Conn.–(BUSINESS... Read more.
ISG to Study UKG Pro Ecosystem Service Providers
Upcoming ISG Provider Lens® report will evaluate providers that modernize workforce operations with AI, data integration and continuous optimization STAMFORD, Conn.–(BUSINESS... Read more.
ISG to Study UKG Pro Ecosystem Service Providers
Upcoming ISG Provider Lens® report will evaluate providers that modernize workforce operations with AI, data integration and continuous optimization STAMFORD, Conn.–(BUSINESS... Read more.
ZFLOW AI’s Simulation-Guided Optimization Identifies a 1.54× Higher-Throughput Serving Configuration for DeepSeek V4-Pro on 8×B300
Working on PaleBlueDot AI’s NVIDIA B300 platform, ZFLOW AI used hardware-aware simulation to find an optimized SGLang serving configuration for high-concurrency... Read more.
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
Daiichi Sankyo and AstraZeneca’s Datroway is the only TROP2 directed antibody drug conjugate to prolong overall survival in this setting versus chemotherapy, with... Read more.
COTY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Coty (COTY) Investors of Securities Class Action Deadline on May 22, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Coty To Contact Him Directly To Discuss Their... Read more.